Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of
bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However,
patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved
to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute
onset and transient cerebral dysfunction and is associated with worse outcomes. Previous
studies indicated that benzodiazepines increase incidence of postoperative delirium.
Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of
this study are to explore the impact of remimazolam for general anesthesia on emergency
delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University First Hospital
Collaborators:
Beijing Tsinghua Chang Gung Hospital Guizhou Provincial People's Hospital Jiangsu Provincial People's Hospital Shanghai 10th People's Hospital The Sixth Medical Center of PLA General Hospital